US Edition23% of AML patients in Phase 2 study see complete remission with...
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
23% of AML patients in Phase 2 study see complete remission with...
Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed KOMET-001 (NCT04067336), the Phase 1/2 trial enrolled participants whose cancer was refractory, meaning it had failed to respond to prior treatments, or relapsed, that is, it came back after initially responding to other treatments. Ziftomenib’s developers Kura Oncology and Kyowa Kiri…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
